BMY : Analysis & Opinions

  1. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  2. A Strong Prognosis For Healthcare Stocks

    November 19, 2013
    Despite the healthcare sectors recent torrid run, there’s still plenty to like about stocks in the industry. Aside from tailwinds ...
  3. A Tale of Two Earnings Reports - Ahead of Wall Street

    October 23, 2013
    The contrasting reports from two bellwethers, Caterpillar and Boeing, shows that pockets of strength notwithstanding, the ...
  4. AstraZeneca Goes Back To The M&A Well Yet Again

    August 26, 2013
    AstraZeneca's acquisition of Amplimmune could pay big dividends in a decade.
  5. Better Margins Can't Hide Merck's Growth Challenges

    July 30, 2013
    Merck's near-term growth is looking weak, but margin improvements and an underestimated pipeline could offer upside.
  6. Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook

    July 30, 2013
    Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook
  7. Glaxo Seeks Tafinlar-Mekinist Approval - Analyst Blog

    July 10, 2013
    GlaxoSmithKline announced that it has submitted supplemental New Drug Applications to the US Food and Drug Administration ...
  8. Positive Data on BMY/ Pfizer's Eliquis - Analyst Blog

    July 3, 2013
    Bristol-Myers and Pfizer presented encouraging data on Eliquis.
  9. Glaxo's Oncology Drugs Get CHMP Nod - Analyst Blog

    July 2, 2013
    The Committee for Medicinal Products for Human Use recommended the approval of Glaxo's Tafinlar and Tyverb.
  10. Stock Market News for June 27, 2013 - Market News

    June 27, 2013
    Weaker-than-expected GDP numbers eased investor concerns that the Federal Reserve would decrease monetary stimulus in the ...
  11. Simcere to Sell Stake in Jilin Boda - Analyst Blog

    June 26, 2013
    Simcere Pharmaceutical Group recently announced that it has signed a share transfer agreement with Zhuhai Rongding Equity ...
  12. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  13. Data on Lilly's Dulaglutide at ADA - Analyst Blog

    June 24, 2013
    Detailed safety and efficacy data on dulaglutide was presented from three phase III AWARD trials at the American Diabetes ...
  14. AstraZeneca/BMY Present Forxiga Data - Analyst Blog

    June 24, 2013
    AstraZeneca and Bristol-Myers Squibb Company announced results from a phase IIa pilot study on Forxiga
  15. Another Setback for Idenix - Analyst Blog

    June 21, 2013
    The FDA has asked the company to provide additional preclinical safety information on IDX20963 before it can commence clinical ...
  16. AstraZeneca and BMY Drug Disappoints - Analyst Blog

    June 20, 2013
    AstraZeneca and Bristol-Myers announced disappointing top-line data from a phase IV study on Onglyza
  17. Data on BMY/ AbbVie's elotuzumab - Analyst Blog

    June 17, 2013
    Bristol-Myers and partner AbbVie presented data on elotuzumab from a phase II study.
  18. After A Good Run, Novartis Looks Fairly Valued

    June 12, 2013
    Novartis is a well-balanced, high-quality pharma with growth credentials, but also a fair valuation today.
  19. Top-Performing Dividend Payers in Health Care with the Most Upside ...

    June 8, 2013
    It is not unusual for stocks on a tear to overrun their mean price targets, which is a signal of how far analysts on average ...
  20. Roche, Reloaded

    May 21, 2013
    Roche has one of the best long-term growth profiles in the Big Pharma space
  21. After A Big Rally, Pfizer Might Need Some Rest

    May 21, 2013
    A big rally has brought Pfizer back to fair value.
  22. Adasuve Deal Is Very Good For Alexza, But What About Teva?

    May 9, 2013
    Teva's partnership with Alexza looks like an expensive gamble.
  23. The “Healthy” Play In Contract Research Organizations

    April 17, 2013
    The pharmaceutical industry is under pressure to do more with less. That means it will be farming out many of is mundane ...
  24. Vical's Loss Narrower than Expected - Analyst Blog

    February 8, 2013
    Vical Inc. (VICL) suffered a net loss per share of 9 cents in the fourth quarter of 2012, narrower than the Zacks Consensus ...
  25. Generics Continue to Hurt Sanofi - Analyst Blog

    February 8, 2013
    Sanofi (SNY) reported fourth quarter 2012 business earnings of 77 cents per American Depository Share (ADS), in line with ...
  26. Pipeline Setback for Idenix - Analyst Blog

    February 7, 2013
    Idenix Pharmaceuticals, Inc. (IDIX) recently announced that the company has decided to discontinue its clinical development ...
  27. Alkermes Turns to Profit, Ups View - Analyst Blog

    February 1, 2013
    Alkermes plc (ALKS) reported earnings of 14 cents per share in the third quarter of fiscal 2013 (ended December 31, 2012). ...
  28. Stock Market News for January 30, 2013 - Market News

    January 30, 2013
    Better-than-expected quarterly results once again guided the S&P 500 and the Dow Jones into the green on Tuesday. Strong ...
  29. MedTech Industry Stock Outlook - Jan 2013 - Zacks Analyst Interviews

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  30. MedTech Industry Stock Outlook - Jan 2013 - Industry Outlook

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  31. Cadence Forecasts Ofirmev Sales - Analyst Blog

    January 25, 2013
    Cadence Pharmaceuticals Inc. (CADX) recently announced that it expects preliminary net revenue of Ofirmev (acetaminophen) ...
  32. Label Expansion for Roche's Avastin - Analyst Blog

    January 24, 2013
    The US Food and Drug Administration (FDA) recently approved Roche's (RHHBY) Avastin (bevacizumab) in combination with fluoropyrimidine-based ...
  33. Brackish Waters for the Market to Swim - Analyst Blog

    January 24, 2013
    We will see a very interesting interplay of competing forces in today's market action, with the Apple (AAPL) overhang and ...
  34. Ahead of Wall Street - January 24, 2013 - Ahead of Wall Street

    January 24, 2013
    Thursday, January 24, 2013 We will see a very interesting interplay of competing forces in today's market action, with ...
  35. CHMP Positive on Pfizer's Bosutinib - Analyst Blog

    January 23, 2013
    Pfizer Inc. (PFE) recently received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal ...
  36. Bristol-Myers Preview: Will it Miss? - Analyst Blog

    January 21, 2013
    Bristol-Myers Squibb Company (BMY) is scheduled to release its fourth-quarter 2012 results before the opening bell on Thursday, ...
  37. Why Smart Investors Are Pouring Trillions into This Type Of Stock

    January 18, 2013
    For decades, analysts have heralded small-cap stocks as the real growers in the stock market. And they're right to some extent; ...
  38. Management Expands at AstraZeneca - Analyst Blog

    January 17, 2013
    AstraZeneca (AZN) recently announced that the company has created seven positions in the senior executive team. At the same ...
  39. Canadian Approval for BMY's Drug - Analyst Blog

    January 16, 2013
    Good news flowed in at Bristol-Myers Squibb (BMY) from Canada when Health Canada, the federal department responsible for ...
  40. Setback for ArQule, Shares Fall - Analyst Blog

    January 14, 2013
    ArQule Inc. (ARQL) and partner Daiichi Sankyo recently announced disappointing phase II results on oncology candidate, tivantinib ...
  41. J&J Drug Supported by FDA Panel - Analyst Blog

    January 14, 2013
    Janssen Research & Development, LLC, a Johnson & Johnson (JNJ) company, recently announced that the FDA's Endocrinologic ...
  42. Lilly to Go Solo with LY2605541 - Analyst Blog

    January 11, 2013
    Eli Lilly and Company (LLY) recently announced that it will be developing diabetes candidate, LY2605541, on its own. The ...
  43. Positive Results on MDCO's Cangrelor - Analyst Blog

    January 10, 2013
    The Medicines Company (MDCO) recently received good news with the company announcing positive results on its phase III candidate, ...
  44. Stock Market News for January 8, 2013 - Market News

    January 8, 2013
    Investor apprehensions surrounding fourth-quarter earnings dragged benchmarks into negative territory on Monday. Indices ...
  45. Abbott Labs Spins Off AbbVie: Which Is The Better Buy?

    January 4, 2013
    January 2 was the first day of trading for the pharmaceutical spin-off.
  46. US Approval for Eliquis - Analyst Blog

    December 31, 2012
    Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer Inc. (PFE) received some encouraging news when the US Food ...
  47. Stock Market News for December 20, 2012 - Market News

    December 20, 2012
    Talks between Democrats and Republicans on the Fiscal Cliff issue took a negative turn, dragging the benchmarks into the ...
  48. The Absolute Highest Yields You'll Find... in 8 Major Sectors

    December 13, 2012
    Readers of my articles should know by now that I'm always on the lookout for good dividend-paying ideas. There's no better ...
  49. BMY/ABT Present Oncology Data - Analyst Blog

    December 12, 2012
    Bristol-Myers Squibb Company (BMY) and partner Abbott Laboratories (ABT) recently presented data on their oncology candidate ...
  50. Life Technologies Stays Neutral - Analyst Blog

    December 7, 2012
    We have reaffirmed our Neutral recommendation on Life Technologies (LIFE) with a target price of $52.00. The company's ...
  51. Pharma & Biotech Stock Outlook - Dec 2012 - Zacks Analyst Interviews

    December 6, 2012
    The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The ...
  52. Pharma & Biotech Stock Outlook - Dec 2012 - Industry Outlook

    December 6, 2012
    The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The ...
  53. NVO Reports Positive Victoza Data - Analyst Blog

    November 29, 2012
    Novo Nordisk (NVO) recently announced data from the post-hoc analysis of two phase III b studies on Victoza (liraglutide) ...
  54. Another Generic from Dr. Reddy's - Analyst Blog

    November 23, 2012
    Dr. Reddy's Laboratories (RDY) recently launched its generic version of Pfizer's (PFE) pulmonary arterial hypertension (PAH) ...
  55. BMY/PFE's Eliquis Cleared in the EU - Analyst Blog

    November 21, 2012
    Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer Inc. (PFE) received some encouraging news with the European ...
  56. Simcere 3Q Earnings Matches - Analyst Blog

    November 19, 2012
    Simcere Pharmaceutical Group (SCR) reported third quarter 2012 earnings of 7 cents per American Depositary Share (ADS), in ...
  57. Alkermes Reverts to Neutral - Analyst Blog

    November 16, 2012
    We are reverting to a Neutral recommendation on Alkermes plc (ALKS) from Outperform as we believe that the stock is fairly ...
  58. AZN's Forxiga Gets EU Approval - Analyst Blog

    November 15, 2012
    Recently, AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) announced that their type II diabetes candidate, Forxiga (dapagliflozin) ...
  59. The Cliff and Other Concerns - Analyst Blog

    November 9, 2012
    On Thursday, the major U.S. stock indices fell for the second day in a row with the S&P 500 moving below its 200-day moving ...
  60. Jazz Pharma 3Q Earnings In Line - Analyst Blog

    November 9, 2012
    Jazz Pharmaceuticals plc (JAZZ) reported third quarter 2012 earnings (including share-based compensation charges but excluding ...
  61. Revenues Rise at Alkermes - Analyst Blog

    November 5, 2012
    Alkermes plc (ALKS) reported earnings of 3 cents per share (including depreciation and stock-based compensation expenses) ...
  62. Strong Quarter at Novo Nordisk - Analyst Blog

    November 2, 2012
    Novo Nordisk (NVO) reported second quarter 2012 earnings of $1.67 per American Depository Receipt (ADR), up 20.1% from the ...
  63. Solid Quarter at Dr. Reddy's - Analyst Blog

    October 31, 2012
    Dr. Reddy's Laboratories (RDY) reported second quarter fiscal 2013 earnings per American Depositary Share (ADS) of 50 cents, ...
  64. Generic Erosion Hurts AstraZeneca - Analyst Blog

    October 26, 2012
    AstraZeneca's (AZN) third quarter 2012 core earnings of $1.51 per American Depositary Share (ADS) beat the Zacks Consensus ...
  65. Jazz Divests Women's Health Suite - Analyst Blog

    October 22, 2012
    Jazz Pharmaceuticals plc (JAZZ) recently completed the sale of its women's health business to Meda Pharmaceuticals Inc., ...
  66. LIFE Continues Acquisition Spree - Analyst Blog

    October 9, 2012
    Life Technologies (LIFE) is on an acquisition bandwagon, targeted towards building its diagnostics franchise. The company ...
  67. AstraZeneca Licenses Ardelyx's Drugs - Analyst Blog

    October 9, 2012
    AstraZeneca (AZN) recently announced that it has entered into a global exclusive licensing agreement with Ardelyx for the ...
  68. New Target Date for BMY/PFE's Eliquis - Analyst Blog

    September 27, 2012
    The US approval process of Bristol-Myers Squibb Company/Pfizer Inc.'s (BMY/PFE) anti-clotting drug Eliquis (apixaban) is ...
  69. NVS Drugs Get Positive CHMP Opinion - Analyst Blog

    September 26, 2012
    The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently provided two positive ...
  70. LIFE Grows Diagnostics Portfolio - Analyst Blog

    September 26, 2012
    Over the recent past Life Technologies (LIFE) has been focusing on expanding its diagnostics portfolio. To achieve this objective, ...
  71. Life Technologies Remains Neutral - Analyst Blog

    September 24, 2012
    We have reaffirmed our neutral recommendation on Life Technologies (LIFE) with a target price of $51.00. The company's ...
  72. Back to Neutral on Alkermes - Analyst Blog

    September 18, 2012
    We are moving back to a Neutral recommendation on Alkermes plc (ALKS) as we believe the stock is fairly valued at current ...
  73. Life Partners with Bristol-Myers - Analyst Blog

    September 18, 2012
    In an attempt to develop its diagnostics business, Life Technologies (LIFE) entered into a Master Development Agreement with ...
  74. Vical and Bristol-Myers Ink Deal - Analyst Blog

    September 17, 2012
    Vical Incorporated (VICL) recently signed an agreement with Bristol-Myers Squibb Company (BMY) providing the latter with ...
  75. Balanced View on Gilead - Analyst Blog

    September 7, 2012
    We are maintaining our Neutral recommendation on Gilead Sciences, Inc. (GILD) with a target price of $61.00. The stock carries ...
  76. ARIAD Seeks EU Nod for Ponatinib - Analyst Blog

    August 31, 2012
    ARIAD Pharmaceuticals, Inc. (ARIA) recently submitted a Marketing Authorization Application (MAA) for its BCR-ABL inhibitor, ...
  77. The Week In Healthcare

    August 31, 2012
    Although this has been a solid year for med-tech, some sub-sectors are starting to lag a bit during this late summer rally.
  78. Gilead's Stribild Gets FDA Nod - Analyst Blog

    August 29, 2012
    Gilead Sciences, Inc. (GILD) recently gained US Food and Drug Administration (FDA) approval for its HIV combination pill, ...
  79. AstraZeneca Recruits New CEO - Analyst Blog

    August 29, 2012
    AstraZeneca (AZN) recently announced that Pascal Soriot has been recruited as the new Chief Executive Officer (CEO) of the ...
  80. Par Pharma's 'Go Shop' Period Ends - Analyst Blog

    August 29, 2012
    Par Pharmaceuticals Companies Inc. (PRX) recently announced that the "go shop" period under the terms of the earlier announced ...
  81. The Week Ahead In Healthcare

    August 27, 2012
    Here are some events happening this week that will impact the medical technology sector. Although this has been a solid year ...
  82. Simcere Misses 2Q Estimates - Analyst Blog

    August 13, 2012
    Simcere Pharmaceutical Group's (SCR) second quarter 2012 earnings of 8 cents per American Depositary Share (ADS), a couple ...
  83. Big Movers on the Healthcare Sector Today, Including BMY

    August 2, 2012
    It's been a bad day for the market after the morning's trading. The Nasdaq has fallen 0.4%; the S&P 500 has declined 0.8%; ...
  84. Portfolio Pruning 101

    July 27, 2012
    MoneyShow's Tom Aspray takes an in-depth look at his successful Charts in Play Portfolio, as he looks to take profits on ...
  85. Generic Plavix & Avapro Hurt Sanofi - Analyst Blog

    July 27, 2012
    Sanofi (SNY) reported second quarter 2012 business earnings of 95 cents per American Depository Share (ADS), much lower than ...
  86. Earnings Preview: Bristol-Myers - Analyst Blog

    July 23, 2012
    Biopharmaceutical giant  Bristol-Myers Squibb Company (BMY) is all set to unveil  its second quarter 2012 results before ...
  87. Dr. Reddy's Launches Generic Lipitor - Analyst Blog

    July 19, 2012
    Yet another generic version of Pfizer's (PFE) cholesterol drug, Lipitor (atorvastatin calcium), entered the market recently ...
  88. TPG to Acquire Par Pharma for $1.9B - Analyst Blog

    July 17, 2012
    Yet another acquisition agreement was recently announced in the pharma sector. US based specialty pharmaceutical company ...
  89. Merck KGaA's Erbitux Disappoints - Analyst Blog

    July 10, 2012
    Merck KGaA (MKGAF) recently announced that Erbitux failed to achieve its primary endpoint in the phase III EXPAND trial, ...
  90. FDA Approves Qiagen's KRAS Test - Analyst Blog

    July 9, 2012
    Molecular diagnostics solutions provider, Qiagen (QGEN) recently got the nod of the U.S. Food and Drug Administration ("FDA") ...
  91. Setback for Chelsea Therapeutics - Analyst Blog

    July 6, 2012
    Chelsea Therapeutics International, Ltd. (CHTP) recently suffered a setback when the US Food and Drug Administration (FDA), ...
  92. GolinHarris Acquires Virgo Health - Analyst Blog

    July 6, 2012
    GolinHarris, a division of Interpublic Group (IPG) intends to acquire Virgo Heath, an independent UK-based Healthcare Communications ...
  93. Reddy Adds to Generic Portfolio - Analyst Blog

    July 5, 2012
    Dr. Reddy's Laboratories (RDY) recently announced the launch of its generic version of Roche's (RHHBY) Boniva following the ...
  94. Company News for July 3, 2012 - Corporate Summary

    July 3, 2012
    "    Speculations that founder Dick Schulze might turn Best Buy Co., Inc. (NYSE:BBY) into a private company helped the company's ...
  95. Gilead Seeks FDA OK for Cobicistat - Analyst Blog

    July 2, 2012
    Recently, Gilead Sciences, Inc. (GILD) announced that it has filed a marketing application seeking approval for its HIV candidate, ...
  96. Bristol-Myers/Pfizer get CRL - Analyst Blog

    June 28, 2012
    Recently, Bristol-Myers Squibb (BMY) and partner, Pfizer Inc. (PFE), suffered a setback when the US Food and Drug Administration ...
  97. BMY, Emory University Join Forces - Analyst Blog

    June 21, 2012
    Recently, Bristol-Myers Squibb Company (BMY) inked a deal with Emory University for the development of the former's pipeline ...
  98. BMY Presents Data on Sprycel - Analyst Blog

    June 18, 2012
    Recently, Bristol-Myers Squibb Company (BMY) and partner Otsuka Pharmaceutical Europe Ltd. presented six-year follow-up data ...
  99. Bristol-Myers Shares Positive Data - Analyst Blog

    June 11, 2012
    Recently, Bristol-Myers Squibb (BMY) and partner AstraZeneca (AZN) presented encouraging data from a phase III study (n=447) ...
  100. BMY Presents Positive Data - Analyst Blog

    June 6, 2012
    Bristol-Myers Squibb Company (BMY) recently presented encouraging data from a late-stage study (AMPLE: n=646), which evaluated ...
  101. Merck Biding Its Time

    May 4, 2012
    Merck investors are getting paid to wait until top-line trends improve.
  102. Eli Lilly Paying Investors To Wait

    May 3, 2012
    The pharmaceutical giant reported decent first quarter results late in April 2012. However, It will likely be some time before ...
  103. Amylin Puts Up 'For Sale' Sign

    April 25, 2012
    A possible sale of Amylin might not be such a bad thing.
  104. 15 Biotech Companies Waiting For FDA Approval

    March 21, 2012
    Despite all of these uncertainties, investors still heavily focus on whether a company's new drug will be approved by the ...
  105. Pfizer Shrugs Off the Loss Of Lipitor

    February 6, 2012
    Pfizer remains very profitable and has ample cushion to adjust its cost structure to maintain a respectable level of profit ...
  106. Big Buys In Share Buybacks

    January 27, 2012
    Record corporate profits and super low interest rates are resulting in a shrinking market environment and a rise in share ...
  107. 2011 In Review - Pharmaceuticals

    December 29, 2011
    2011 was a surprisingly healthy year for drug stocks.
  108. Is Third Time The Charm For Gilead?

    November 22, 2011
    Gilead is going all in on Hep C, as it acquires Pharmasset in a massive deal.
  109. PerkinElmer Adds High-End Tools To Its Box

    September 13, 2011
    Caliper's rebound comes to an end with a premium take-out by PerkinElmer.
  110. Betting On Healthcare's Growth Engine

    August 17, 2011
    In the wake of big pharma's patent cliff and slowing R&D spending, the biotech sector is looking good for investors.
  111. Top Dividend Stocks Owned By The Pros

    August 2, 2011
    Selecting from the top dividend stocks owned by professional investors may give your portfolio a boost.
  112. Top Healthcare Dividend Stocks

    July 26, 2011
    Healthcare stocks are one attractive area in which you can reap dividend income while waiting for the sector to grow.
  113. 10 Drug Stocks for Safety and Yields

    June 26, 2011
    Big pharma is an attractive destination for traders and investors looking for safety, yields, and solid value in the current ...
  114. More To Merck Than Meets The Eye?

    June 22, 2011
    Merck is set up to exceed low-ball estimates.
  115. A Dull ASCO And The Usual Sell-Off

    June 7, 2011
    Investors shouldn't be spooked by the normal post-ASCO sell-off
  116. 4 Stocks Hitting Highs During The Pullback

    May 6, 2011
    Four stocks that are holding up well during a short-term market pullback.
  117. Novo Nordisk Still One Of The Best Around

    May 3, 2011
    Novo Nordisk is one of the best pharmaceutical companies in the world - and it's priced accordingly.
  118. A Foursome Of Pharma Earnings Suggests Business Is Still Tough

    January 31, 2011
    There's little growth to excite pharma investors, but there is more value here than some realize.
  119. Should Investors Take A Chance On Savient?

    October 26, 2010
    Savient's inability to sell itself puts almost everything about the company's value in flux.
  120. Pfizer's King For A Day

    October 14, 2010
    Pfizer does a deal that is good, but not great.
  121. Roll With Your Spinoff

    August 17, 2010
    If you own a stock that's contemplating a spinoff, consider the possibility that the new entity rather than the parent is ...
  122. Big Pharma's Big Problem

    August 16, 2010
    Big Pharma's best patents are expiring, but it may be able to reinvent itself through acquisitions.
  123. The Rest Of The Disappointing Story

    July 23, 2010
    There's more to the story than one lousy quarter for PetMed Express and Gilead.
  124. Novartis On The Right Track

    July 19, 2010
    With recent sales increases and a solid pipeline, Novartis deserves a spot on the watchlist of anybody looking at Big Pharma.
  125. Best Large Cap Stocks In June 2010

    July 6, 2010
    The stock market may have had a terrible performance in June, but many stocks have defied the negative market trend.
  126. Value Picks From A Top Money Manager

    June 23, 2010
    Take a peek into the portfolios of a top performing, value-oriented money manager.
  127. Forest Labs Shows What Cash Can Do

    May 21, 2010
    When Forest Labs' management realizes that its shares are cheap, the best use of the balance will be to buy back the shares.
  128. Gilead's Uncertain Future

    April 26, 2010
    Despite a coming wave of patent expirations, Gilead's stock still deserves a further look.
  129. Dividends With Earnings Growth

    April 23, 2010
    These healthcare and pharma companies have a solid dividend and increasing earnings over the last five years.
  130. Drug Stocks That Deserve A Closer Look

    February 19, 2010
    Pharmaceutical stocks have a bright future, and one of my top choices in the space is Merck, which recently released quarterly ...
  131. The Motorola Breakup

    February 16, 2010
    Motorola finally announced its long-awaited breakup, but shareholders shouldn't get their hopes up just yet.
  132. IPO Market Slows Down With Market Correction

    February 10, 2010
    The initial public offering market has recently hit a few bumps, as investors become nervous about the overall stock market.
  133. Downside Risk At Mead Johnson

    February 2, 2010
    Mead Johnson is the only pure-play option to gain exposure to the stable pediatric nutritional market.
  134. 4 Stocks With Recently Raised Annual Dividends

    January 22, 2010
    A raise in dividends is a vote of confidence in current and future earnings.
  135. A Review Of The Drug Makers Of 2009

    December 29, 2009
    Corporate deal-making was the name of the big pharma game in 2009 and will likely continue into the new year.
  136. The Best IPOs Of 2009

    December 16, 2009
    Chinese companies stole the show in the initial public offering market in 2009, making some lucky (or smart) investors very ...
  137. Four Healthcare Stocks On Fire

    November 18, 2009
    Fourth healthcare stocks that have brushed aside any potential adversity that could arise from future legislation for the ...
  138. The 5 Most Important Drugs In America

    July 28, 2009
    A look at the top-selling drugs finds that a few that make more of a difference to the company's bottom line than others.
  139. 5 Stocks With Low P/Es And High Dividends

    June 19, 2009
    Finding undervalued gems can help boost porfolio returns. Check out five potential diamonds in the rough.
  140. April Large Cap Losers

    May 4, 2009
    The large cap loser list for April consists of former safe havens that have suffered from investor shifts to sectors that ...
  141. Big Pharma's Buying Spree

    April 24, 2009
    A look at recent merger and acquisition activity in the pharmaceutical sector and possible opportunities if the trend continues.
  142. A Thawing For IPOs

    April 23, 2009
    There are some signs of a thawing in the IPO market, though investors should not expect a flurry of new activity.
  143. Is The IPO Logjam About To Break?

    April 16, 2009
    This has been the quietest IPO period that I can remember, but a smattering of new issues might be seen as indicative of ...
  144. Halliburton's A-Bubblin' A Win Over Expectations

    March 16, 2009
    A company that beats earnings estimates may be on track for solid performance going forward.
  145. Why A Merck/Schering Combo Makes Sense

    March 12, 2009
    The Merck/Schering marriage might be a winning combination for both the companies and investors.
  146. Dividend Darlings For February 25

    February 25, 2009
    Companies with a high forward dividend yield could provide a smile at least four times a year.
  147. Abbott: The New Healthcare Bellwether

    January 27, 2009
    The healthcare industry fell 24.5% in 2008. Abbott fell 4%. Any questions?
  148. Bristol-Myers Squibb Could Rise To Old Highs

    November 19, 2008
    Flush with cash and growth prospects, Bristol makes the case to be a core healthcare holding.
  149. Missing Forest Labs For The Trees

    October 27, 2008
    Forest Labs is facing a lull in its pipeline, but prior lulls have been good buying opportunities.
  150. Is Stock Market Capitulation Over?

    October 15, 2008
    We examine the present market for clues to where and when we'll see a bottom.
  151. Putting The Imclone Acquisition Under The Microscope

    October 7, 2008
    The acquisition of the cancer drug maker is not the slam-dunk that Eli Lilly might like investors to think it is.
  152. What Imclone Means To Eli Lilly

    October 7, 2008
    Eli Lilly expands its cancer offering with the acquisition of Imclone. Can the union boost Eli Lilly's floundering stock ...
  153. The Contrarian Case For Pfizer

    August 29, 2008
    Pfizer has plenty of free cash for R&D or acquisitions, and its low forward P/E provides a solid margin of safety.
  154. Duke Energy Is High Yield Royalty

    March 4, 2008
    Duke Energy's very healthy dividend yield makes it a solid investment as a fixed-income proxy, especially during a flight ...
  155. Genentech Propped Up By Drug Pipeline (DNA)

    January 18, 2008
    Genentech released numbers that beat estimates, but the stock still dropped to some disappointing sales figures. Is this ...
  156. Leap Of Faith Healing (MEDX, PDLI, AMLN)

    August 8, 2007
    Make the leap with three pharmaceutical companies who require investor courage but could provide a healthy return.
  157. Johnson & Johnson Blows Away Q1 (JNJ)

    April 20, 2007
    J&J beat its Q1 consensus number with ease, so where is the stock is headed from here?
  158. Generic Manufacturers Go After Big Pharma

    March 14, 2007
    Generic drug manufacturers continue pose a potent threat to the established "big pharma" companies.
  159. On A Pullback, Pfizer Looks Like A Good Bet (PFE)

    December 4, 2006
    Despite its recent setbacks, PFE still remains an attractive buy -- at the right price.
  160. Merck's Worth A Look (MRK)

    August 14, 2006
    Despite Merck's foibles, a cure could be on the way.
Investing News
  1. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  2. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  3. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  4. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
  5. What Is Worse Than Being At Risk?

    You may have heard the old adage: “What is worse than being lost? Not knowing you are lost.” ...
  6. Can Paying Off Your Mortgage Early Hurt Your Net Worth?

    Saving your money and making double or even triple payments on a mortgage may sound productive, ...
Trading Center